ClinicalTrials.gg
RecruitingNCT06422585Updated May 21, 2024

Comparison of Different Analgesic Nerve Blocks in Total Knee Replacement Surgery

An observational study in Knee Prosthesis and Pain, Procedural, sponsored by Azienda Ospedaliero, Universitaria Pisana. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Azienda Ospedaliero, Universitaria Pisana · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to compare the equivalent analgesic efficacy of three regional anesthesia techniques in total knee replacement surgery. The main question it aims to answer is:

  • Non inferiority of each technique in relation to the others Participants will receive selective spinal anesthesia and the antalgic nerve block depending on the group they happen to be in.

Researchers will compare the Femoral Nerve Group+IPACK block, the Saphenous Nerve block+IPACK and the Subsartorial Block groups to see if there is any difference in the pain control in the 24 hours after the surgery.

Read the detailed description

After adequate venous access is obtained, a light sedation with Midazolam 1-2 mg is administered. The patient will be monitored and a selective spinal anesthesia will be performed. After the neuraxial procedure the antalgic block of choice is performed with about 40 mL of long acting local anesthetic.

Magnesium Solfate 1g and Dexametasone 4mg are administered after the block. If the patient wishes, a propofol continuos infusion may be administered for sedation during the surgery. Before the patient leaves the OR, Ketorolac 30mg will be administered.

Pain control after surgery will be achieved with acetaminophen 1g t.i.d., Ketorolac 30mg on demand, and Morphine solfate if NRS >5 after Ketorolac.

Every 6 hours the patient will be monitored by the anesthesia team. After 24 hours the antalgic effect of the nerve block is reasonably thought to be over, so the follow up is interrupted.

02

Conditions studied

  • Knee Prosthesis
  • Pain, Procedural

Browse trials for

Keywords

  • Knee
  • Post procedural pain
  • Regional anesthesia
03

In context

Pain, Procedural

241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.

This study's planned enrollment of 180 is close to the median of 200 across 13 observational studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

Azienda Ospedaliero, Universitaria Pisana is the lead sponsor of 57 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients meeting the inclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 y/o
  • Total knee replacement elective surgery

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 y/o
  • Surgery with general anesthesia
  • Patients with coagulopaties
  • Patients in chronic opioid therapy
  • Refuse to sign form
  • Unable to sign informed consent form
  • Know allergies to medication used for analgesia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Femoral Nerve Block + IPACK Block

    After adequate venous access has been obtained, spinal anesthesia with Levobupivacaine will be performed. After which antalgic Femoral Nerve Block and IPACK Block will be performed.

  • Saphenous (Adductor Canal) Block + IPACK Block

    After adequate venous access has been obtained, spinal anesthesia with Levobupivacaine will be performed. After which Saphenous and IPACK Block will be performed.

  • Dual Subsartorial Block

    After adequate venous access has been obtained, spinal anesthesia with Levobupivacaine will be performed. After which Dual Subsartorial Block will be performed.

06

What researchers measure

Primary outcomes

  1. NRS

    To compare the analgesic effect at 24 hours, of a nerve block technique compared to others after selective spinal anesthetic is administerd to achieve surgical anesthesia.Evaluate pain for every group in the first 24 hours post surgery using the Numeric Pain Scale (NRS) assigning a numeric value between zero (no pain) and ten (the worst pain ever felt). Absence of relevant pain is considered a NRS less than three. Success of the block was defined as NRS≤3.

    Time frame: Baseline, every 6 hours for the first 24 hours after surgery

Secondary outcomes

  1. side effect

    Monitoring the onset of side effects (nausea/vomiting/hypotension/dizziness/sensitive impareiment) in every group of patients in the first 24 hours every six hours

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Edificio 3 - Azienda Ospedaliero Universitaria Pisana Cisanello
    Pisa, Toscana 56124, Italy
    Recruiting
    • Serena Ricalzone, MD · Contact050.997881
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
May 21, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Feb 2025
CompletionEst.
Feb 2025
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06422585
Lead sponsor
Azienda Ospedaliero, Universitaria Pisana
Responsible party
Serena Ricalzone (principal investigator, Azienda Ospedaliero, Universitaria Pisana) — Principal investigator
First posted
May 21, 2024
Start date
Feb 1, 2024
Primary completion
Feb 2025 (estimated)
Completion
Feb 2025 (estimated)
Last update
May 21, 2024

Study contacts

Serena Ricalzone, MD
Contact
serenaricalzone@gmail.com
050.997881
Silvia Nardi, MD
study director · Azienda Ospedaliera Universitaria Pisana
Alessandro Cardu, MD
study chair · Scuola Specializzazione - Università di Pisa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion